GPCPD1

Summary

GPCPD1 (glycerophosphocholine phosphodiesterase 1, HGNC:26957) is a protein-coding gene on chromosome 20p12.3, encoding Glycerophosphocholine phosphodiesterase GPCPD1 (Q9NPB8). May be involved in the negative regulation of skeletal muscle differentiation, independently of its glycerophosphocholine phosphodiesterase activity.

Predicted to enable glycerophosphocholine phosphodiesterase activity. Predicted to be involved in glycerophospholipid catabolic process. Predicted to act upstream of or within skeletal muscle tissue development. Predicted to be located in cytosol.

Source: NCBI Gene 56261 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 82 total
• MANE Select transcript: NM_019593

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26957
Approved symbol	GPCPD1
Name	glycerophosphocholine phosphodiesterase 1
Location	20p12.3
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1434, GDE5, GDPD6
Ensembl gene	ENSG00000125772
Ensembl biotype	protein_coding
OMIM	614124
Entrez	56261

Gene structure

Transcript identifiers

Ensembl transcripts: 19 — 14 protein_coding, 2 retained_intron, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000379019, ENST00000418646, ENST00000462080, ENST00000473797, ENST00000481038, ENST00000481690, ENST00000633552, ENST00000718343, ENST00000873924, ENST00000873925, ENST00000873926, ENST00000873927, ENST00000922545, ENST00000922546, ENST00000959744, ENST00000959745, ENST00000959746, ENST00000959747, ENST00000959748

RefSeq mRNA: 1 — MANE Select: NM_019593 NM_019593

CCDS: CCDS13090

Canonical transcript exons

ENST00000379019 — 20 exons

Exon	Start	End
ENSE00001026553	5610842	5611006
ENSE00001653615	5586194	5586269
ENSE00003472832	5565017	5565078
ENSE00003474022	5558684	5558819
ENSE00003491073	5584281	5584322
ENSE00003492572	5598725	5598821
ENSE00003499249	5575413	5575545
ENSE00003500174	5570147	5570239
ENSE00003510368	5578380	5578611
ENSE00003510615	5573915	5573969
ENSE00003510709	5557945	5558105
ENSE00003526831	5567483	5567560
ENSE00003527439	5575816	5575978
ENSE00003542687	5580008	5580131
ENSE00003581846	5593327	5593411
ENSE00003623456	5559940	5560076
ENSE00003626525	5561465	5561530
ENSE00003630006	5566733	5566772
ENSE00003782897	5604364	5604440
ENSE00004034829	5544439	5547850

Expression profiles

Bgee: expression breadth ubiquitous, 256 present calls, max score 97.53.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 49.9843 / max 1979.7405, expressed in 1812 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
186315	43.2031	1806
186314	4.5322	1264
186313	1.5351	591
208980	0.3880	207
186307	0.3260	144

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
palpebral conjunctiva	UBERON:0001812	97.53	gold quality
monocyte	CL:0000576	97.00	gold quality
bone marrow	UBERON:0002371	96.75	gold quality
leukocyte	CL:0000738	96.61	gold quality
bone marrow cell	CL:0002092	96.37	gold quality
endothelial cell	CL:0000115	96.09	gold quality
visceral pleura	UBERON:0002401	95.63	gold quality
calcaneal tendon	UBERON:0003701	95.36	gold quality
tibialis anterior	UBERON:0001385	95.32	gold quality
epithelial cell of pancreas	CL:0000083	94.91	gold quality
trabecular bone tissue	UBERON:0002483	94.65	gold quality
blood	UBERON:0000178	94.62	gold quality
primary visual cortex	UBERON:0002436	94.48	gold quality
Brodmann (1909) area 23	UBERON:0013554	94.12	gold quality
middle temporal gyrus	UBERON:0002771	94.00	gold quality
sperm	CL:0000019	93.97	gold quality
tonsil	UBERON:0002372	93.94	gold quality
cartilage tissue	UBERON:0002418	93.73	gold quality
cerebellar vermis	UBERON:0004720	93.67	gold quality
occipital lobe	UBERON:0002021	93.57	gold quality
tibia	UBERON:0000979	93.52	gold quality
spleen	UBERON:0002106	93.44	gold quality
pancreatic ductal cell	CL:0002079	93.13	gold quality
saliva-secreting gland	UBERON:0001044	93.00	gold quality
esophagus squamous epithelium	UBERON:0006920	93.00	gold quality
minor salivary gland	UBERON:0001830	92.98	gold quality
granulocyte	CL:0000094	92.95	gold quality
lung	UBERON:0002048	92.95	gold quality
parietal pleura	UBERON:0002400	92.88	gold quality
adrenal tissue	UBERON:0018303	92.88	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-3929	yes	192.31
E-ANND-3	yes	9.59

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

234 targeting GPCPD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-196A-5P	100.00	68.16	684
HSA-MIR-196B-5P	100.00	68.16	681
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4262	100.00	73.26	3931
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-6748-5P	100.00	65.81	1057
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996

Literature-anchored findings (GeneRIF, showing 8)

• common genetic variants in GPCPD1 are associated with scaling of visual cortical surface area in humans (PMID:22343285)
• We have identified EDI3, a key enzyme controlling GPC and choline metabolism; Because inhibition of it corrects the GPC/PC ratio and decreases the migration capacity of tumor cells, it represents a possible target for therapeutic intervention. (PMID:22570503)
• EDI3 links choline metabolism to integrin expression, cell adhesion and spreading (PMID:25482527)
• Circular RNA circSNX6 promotes sunitinib resistance in renal cell carcinoma through the miR-1184/GPCPD1/ lysophosphatidic acid axis. (PMID:34626691)
• Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth. (PMID:36670508)
• Hypoxia-induced GPCPD1 depalmitoylation triggers mitophagy via regulating PRKN-mediated ubiquitination of VDAC1. (PMID:36803235)
• Gpcpd1-GPC metabolic pathway is dysfunctional in aging and its deficiency severely perturbs glucose metabolism. (PMID:38238601)
• EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis. (PMID:38816770)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	gpcpd1	ENSDARG00000016011
mus_musculus	Gpcpd1	ENSMUSG00000027346
rattus_norvegicus	Gpcpd1	ENSRNOG00000053201
drosophila_melanogaster	CG2818	FBGN0031566
drosophila_melanogaster	CG9394	FBGN0034588
drosophila_melanogaster	CG11619	FBGN0036836
drosophila_melanogaster	CG18135	FBGN0036837
drosophila_melanogaster	CG3942	FBGN0038008
caenorhabditis_elegans		WBGENE00011511

Protein

Protein identifiers

Glycerophosphocholine phosphodiesterase GPCPD1 — Q9NPB8 (reviewed: Q9NPB8)

Alternative names: Glycerophosphodiester phosphodiesterase 5

All UniProt accessions (4): Q9NPB8, A0A0J9YVP8, A0A0J9YY12, H0Y565

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in the negative regulation of skeletal muscle differentiation, independently of its glycerophosphocholine phosphodiesterase activity.

Subcellular location. Cytoplasm. Cytosol.

Tissue specificity. Widely expressed, with highest expression in spinal chord.

Similarity. Belongs to the glycerophosphoryl diester phosphodiesterase family.

RefSeq proteins (1): NP_062539* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002044	CBM20	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR013784	Carb-bd-like_fold	Homologous_superfamily
IPR017946	PLC-like_Pdiesterase_TIM-brl	Homologous_superfamily
IPR030395	GP_PDE_dom	Domain
IPR034839	CBM20_GPCPD1	Domain
IPR051578	GDPD	Family
IPR057506	C2_GPCPD1	Domain

Pfam: PF00686, PF03009, PF25329

Enzyme classification (BRENDA):

• EC 3.1.4.46 — glycerophosphodiester phosphodiesterase (BRENDA: 38 organisms, 62 substrates, 23 inhibitors, 29 Km, 19 kcat entries)

Substrate kinetics (BRENDA)

10 substrates with measured Km, best-characterized 10. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
BIS(P-NITROPHENYL) PHOSPHATE	0.12–3.95	5
GLYCEROPHOSPHOCHOLINE	0.036–2	5
P-NITROPHENYL PHOSPHATE	0.12–49	5
GLYCEROPHOSPHOETHANOLAMINE	0.2–0.22	3
GLYCEROPHOSPHOGLYCEROL	0.2–0.62	3
BIS(P-NITROPHENYL PHOSPHATE)	3.5–7	2
GLYCEROPHOSPHOINOSITOL	0.39	2
GLYCEROPHOSPHOSERINE	0.66	2
BIS(4-NITROPHENYL) PHOSPHATE	3.56	1
BIS(GLYCEROPHOSPHO)GLYCEROL	0.6	1

Catalyzed reactions (Rhea), 1 shown:

• sn-glycerol 3-phosphocholine + H2O = sn-glycerol 3-phosphate + choline + H(+) (RHEA:16061)

UniProt features (19 total): strand 7, modified residue 3, domain 2, helix 2, binding site 2, chain 1, turn 1, sequence variant 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2Z0B	X-RAY DIFFRACTION	2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NPB8-F1	87.45	0.70

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 70; 88–89

Post-translational modifications (3): 175, 424, 608

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-1483115	Hydrolysis of LPC
R-HSA-1483152	Hydrolysis of LPE

MSigDB gene sets: 228 (showing top): TGGTGCT_MIR29A_MIR29B_MIR29C, AAGCAAT_MIR137, GOBP_PHOSPHOLIPID_METABOLIC_PROCESS, ACTACCT_MIR196A_MIR196B, GOBP_MUSCLE_TISSUE_DEVELOPMENT, IVANOVA_HEMATOPOIESIS_MATURE_CELL, MORI_IMMATURE_B_LYMPHOCYTE_UP, GOBP_ORGANOPHOSPHATE_METABOLIC_PROCESS, GOBP_GLYCEROLIPID_METABOLIC_PROCESS, GERY_CEBP_TARGETS, UEDA_PERIFERAL_CLOCK, GOBP_MUSCLE_STRUCTURE_DEVELOPMENT, INGRAM_SHH_TARGETS_UP, GOBP_SKELETAL_MUSCLE_ORGAN_DEVELOPMENT, GOBP_ORGANOPHOSPHATE_CATABOLIC_PROCESS

GO Biological Process (3): skeletal muscle tissue development (GO:0007519), glycerophospholipid catabolic process (GO:0046475), lipid metabolic process (GO:0006629)

GO Molecular Function (6): glycerophosphocholine phosphodiesterase activity (GO:0047389), starch binding (GO:2001070), protein binding (GO:0005515), phosphoric diester hydrolase activity (GO:0008081), hydrolase activity (GO:0016787), carbohydrate binding (GO:0030246)

GO Cellular Component (2): cytosol (GO:0005829), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Glycerophospholipid biosynthesis	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
cellular anatomical structure	2
striated muscle tissue development	1
skeletal muscle organ development	1
glycerophospholipid metabolic process	1
phospholipid catabolic process	1
glycerolipid catabolic process	1
primary metabolic process	1
phosphoric diester hydrolase activity	1
polysaccharide binding	1
phosphoric ester hydrolase activity	1
catalytic activity	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

1269 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GPCPD1	GDPD5	Q8WTR4	589
GPCPD1	CHPT1	Q8WUD6	588
GPCPD1	CHKA	P35790	553
GPCPD1	GDE1	Q9NZC3	536
GPCPD1	TATDN3	Q17R31	530
GPCPD1	CEPT1	Q9Y6K0	514
GPCPD1	OTOL1	A6NHN0	472
GPCPD1	ANGEL2	Q5VTE6	470
GPCPD1	PCYT1B	Q9Y5K3	464
GPCPD1	TDRP	Q86YL5	455
GPCPD1	BEND7	Q8N7W2	453
GPCPD1	TMX4	Q9H1E5	449
GPCPD1	SHLD1	Q8IYI0	443
GPCPD1	LYPLA1	O75608	434
GPCPD1	UTP20	O75691	433

IntAct

7 interactions, top by confidence:

A	B	Type	Score
SLC35D3	GPCPD1	psi-mi:“MI:0915”(physical association)	0.670
GPCPD1	TK1	psi-mi:“MI:0915”(physical association)	0.370
SLC35D3	ATP6V0A1	psi-mi:“MI:0914”(association)	0.350
PCBD1	PTPDC1	psi-mi:“MI:0914”(association)	0.350
ZNF418	ZNF195	psi-mi:“MI:0914”(association)	0.350
SLC35D3	ERLIN2	psi-mi:“MI:0914”(association)	0.350

BioGRID (14): GPCPD1 (Affinity Capture-MS), GPCPD1 (Affinity Capture-MS), GPCPD1 (Affinity Capture-MS), GPCPD1 (Affinity Capture-MS), GPCPD1 (Affinity Capture-MS), LYPLA1 (Affinity Capture-Western), GPCPD1 (Affinity Capture-Western), VDAC1 (Affinity Capture-MS), VDAC1 (Affinity Capture-Western), GPCPD1 (Affinity Capture-Western), GPCPD1 (Affinity Capture-MS), GPCPD1 (Affinity Capture-RNA), GPCPD1 (Proximity Label-MS), GPCPD1 (Two-hybrid)

ESM2 similar proteins: A0JN80, A2RV18, A2VE39, D2HRF1, D3ZG52, D3ZVK1, E1BMP7, G3GTP0, I0IUP3, O02697, P0DM58, P37202, P42338, P48736, P49717, P49917, Q08162, Q0P4R5, Q0V9Q6, Q0V9R3, Q0WPN0, Q17632, Q3EBC8, Q3V3E1, Q5F310, Q5R5N8, Q5R6L3, Q5R981, Q5U2P0, Q5U2Z5, Q5ZKG3, Q6GN11, Q6NQJ6, Q80VJ4, Q8BTF7, Q8BTI9, Q8C0L9, Q8C0S1, Q8CI75, Q8N1G2

Diamond homologs: A0A1D8PNZ7, A2X8A7, A2XNL6, A2Y8U6, P43585, P77736, Q02979, Q10003, Q10B79, Q21407, Q2V4F9, Q658H5, Q680A6, Q6EPQ3, Q74ZH9, Q80VJ4, Q8C0L9, Q8RB32, Q94A21, Q9NPB8, Q9SGA2, Q9ULT8, O14169, O90760, Q10728, Q1RJ28, Q5UQV3, Q9DBR7, Q9JL55, Q9JL56, Q9NZC3, O07592, Q9C104, P37965, Q3T0T0, Q86WC6, Q9D119, Q9FLM1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

82 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	57
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

3629 predictions. Top by Δscore:

Variant	Effect	Δscore
20:5557966:A:C	donor_gain	1.0000
20:5557969:C:CA	donor_gain	1.0000
20:5557975:T:A	donor_gain	1.0000
20:5557985:T:A	donor_gain	1.0000
20:5558678:A:C	donor_gain	1.0000
20:5558680:TTA:T	donor_loss	1.0000
20:5558681:TA:T	donor_loss	1.0000
20:5558682:A:AC	donor_gain	1.0000
20:5558682:A:AT	donor_loss	1.0000
20:5558682:AC:A	donor_gain	1.0000
20:5558683:C:CG	donor_gain	1.0000
20:5558683:CC:C	donor_gain	1.0000
20:5558683:CCA:C	donor_gain	1.0000
20:5558683:CCAG:C	donor_gain	1.0000
20:5558683:CCAGT:C	donor_gain	1.0000
20:5558815:GAACC:G	acceptor_gain	1.0000
20:5558817:ACC:A	acceptor_gain	1.0000
20:5558818:CC:C	acceptor_gain	1.0000
20:5558818:CCC:C	acceptor_gain	1.0000
20:5558819:CC:C	acceptor_gain	1.0000
20:5558820:C:CA	acceptor_loss	1.0000
20:5558820:C:CC	acceptor_gain	1.0000
20:5558820:C:T	acceptor_gain	1.0000
20:5558821:T:A	acceptor_loss	1.0000
20:5559938:A:AC	donor_gain	1.0000
20:5559939:C:CC	donor_gain	1.0000
20:5559939:CATT:C	donor_gain	1.0000
20:5560076:CCTAG:C	acceptor_gain	1.0000
20:5561578:C:CT	acceptor_gain	1.0000
20:5561579:A:T	acceptor_gain	1.0000

AlphaMissense

4446 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
20:5558021:A:G	W585R	0.999
20:5558021:A:T	W585R	0.999
20:5558104:C:T	G557E	0.999
20:5558105:C:A	G557W	0.999
20:5558105:C:G	G557R	0.999
20:5558105:C:T	G557R	0.999
20:5558735:T:A	R539S	0.999
20:5558735:T:G	R539S	0.999
20:5558736:C:G	R539T	0.999
20:5558807:C:A	K515N	0.999
20:5558807:C:G	K515N	0.999
20:5559945:G:C	C509W	0.999
20:5559960:A:C	F504L	0.999
20:5559960:A:T	F504L	0.999
20:5559962:A:G	F504L	0.999
20:5559981:C:A	R497S	0.999
20:5559981:C:G	R497S	0.999
20:5561483:T:A	K459N	0.999
20:5561483:T:G	K459N	0.999
20:5561484:T:A	K459I	0.999
20:5567496:A:G	L405P	0.999
20:5573925:G:T	A349D	0.999
20:5573948:A:C	N341K	0.999
20:5573948:A:T	N341K	0.999
20:5575440:C:T	G325D	0.999
20:5575443:C:G	R324P	0.999
20:5575447:G:C	H323D	0.999
20:5575449:C:T	G322D	0.999
20:5580105:A:G	W126R	0.999
20:5580105:A:T	W126R	0.999

dbSNP variants (sampled 300 via entrez): RS1000046252 (20:5554494 C>T), RS1000111597 (20:5593406 A>T), RS1000208723 (20:5611785 C>G,T), RS1000268171 (20:5548016 A>T), RS1000269042 (20:5548780 G>A), RS1000324098 (20:5605576 C>T), RS1000378169 (20:5598540 A>C), RS1000395282 (20:5604968 CAA>C), RS1000472586 (20:5580827 C>T), RS1000473843 (20:5555368 G>A), RS1000556405 (20:5578894 T>A,C), RS1000630136 (20:5587874 C>T), RS1000662111 (20:5592546 C>T), RS1000675275 (20:5560684 C>T), RS1000818703 (20:5585206 G>A)

Disease associations

OMIM: gene MIM:614124 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST001411_1	Occipital cortical area (total cortical area interaction)	6.000000e-09
GCST006473_2	Diffusing capacity of the lung for carbon monoxide traits	4.000000e-07
GCST006616_4	Uterine fibroid number (single vs multiple)	1.000000e-06
GCST009391_2087	Metabolite levels	2.000000e-06
GCST010204_144	Low density lipoprotein cholesterol levels	1.000000e-11
GCST010243_12	Apolipoprotein B levels	1.000000e-13
GCST010245_100	LDL cholesterol levels	2.000000e-08
GCST012232_37	Lipoprotein (a) levels	7.000000e-10

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004771	visual cortical surface area measurement
EFO:0008381	total cortical area measurement
EFO:0009369	diffusing capacity of the lung for carbon monoxide
EFO:0009410	uterine fibroid measurement
EFO:0010373	phosphatidylcholine 32:1 measurement
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004615	apolipoprotein B measurement
EFO:0006925	lipoprotein A measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

58 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects cotreatment, decreases expression, affects expression, increases expression	4
sodium arsenite	decreases expression, affects cotreatment, increases abundance	3
Air Pollutants	affects expression, increases abundance, increases expression	3
Arsenic	affects methylation, affects cotreatment, decreases expression, increases abundance	3
Valproic Acid	affects expression, increases expression	3
Cyclosporine	increases expression	3
methylmercuric chloride	increases expression	2
Acetaminophen	affects expression, increases expression	2
Cadmium	increases abundance, increases expression, decreases expression	2
Folic Acid	decreases expression, affects cotreatment, increases expression	2
Nickel	increases expression	2
Ozone	affects expression, increases abundance	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
GSK-J4	increases expression	1
FR900359	decreases phosphorylation	1
triphenyl phosphate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
resorcinol	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluoro-n-nonanoic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
clothianidin	increases expression	1
ICG 001	increases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, increases expression	1
prothioconazole	increases expression	1
NSC 689534	affects binding, increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Sunitinib	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.